Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
Direct Healthcare Professional Communication (DHPC)
Direct Healthcare Professional Communications
The Summary of Product Characteristics (SPC) is a specific document, the wording of which has been agreed with the regulatory authority as part of the medicine approval process. It is required before any medicine is allowed on the market in Europe. It is designed to assist doctors and pharmacists in prescribing and supplying the product.
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
This medicine and its document have not been updated in the last 30 days.
A direct healthcare professional communication (DHPC) is for healthcare professionals to inform them of important new safety information about a medicine and any actions they should take.
''Company'' may refer to either the Marketing Authorization Holder (MAH), the company responsible for marketing the product in Ireland and/or responsible for uploading documents pertaining to the product onto Medicines.ie. To determine the MAH, please consult the actual submitted documents.